Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,685 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Sato Y, et al. Among authors: hashimoto k. Chest. 2022 Nov;162(5):1188-1198. doi: 10.1016/j.chest.2022.05.035. Epub 2022 Jun 1. Chest. 2022. PMID: 35661746
Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan.
Kikawa Y, Kotake T, Kajiwara Y, Hashimoto K, Yamashiro H, Ohtani S, Takao S, Toi M. Kikawa Y, et al. Among authors: hashimoto k. Breast Cancer (Auckl). 2019 Jan 22;13:1178223418825135. doi: 10.1177/1178223418825135. eCollection 2019. Breast Cancer (Auckl). 2019. PMID: 30733627 Free PMC article.
Correction: Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study.
WakasakiI T, Manako T, YasumatsuI R, Hara H, Toh S, Masuda M, YamauchiID M, Kuratomi Y, Nishimura E, Takeuchi T, Matsuo M, Jiromaru R, Hashimoto K, Komune N, Nakagawa T. WakasakiI T, et al. Among authors: hashimoto k. PLoS One. 2024 May 9;19(5):e0303720. doi: 10.1371/journal.pone.0303720. eCollection 2024. PLoS One. 2024. PMID: 38722895
Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era.
Shindo T, Hashimoto K, Fujino K, Takahashi A, Hotta H, Maeda T, Kunishima Y, Fukuta F, Ito N, Wanifuchi A, Kato R, Okada M, Matsukawa M, Horita H, Takayanagi A, Kobayashi K, Tanaka T, Masumori N. Shindo T, et al. Among authors: hashimoto k. World J Urol. 2024 May 9;42(1):307. doi: 10.1007/s00345-024-04952-z. World J Urol. 2024. PMID: 38722418
Skeletal Muscle Mass Index Reduction Rate as a Prognostic Indicator for Patients Undergoing Pancreatectomy for Pancreatic Cancer.
Mita J, Maeda T, Tsujita E, Hashimoto N, Fujikawa R, Ono Y, Sakai A, Tanaka S, Matono R, Ohmine T, Kometani T, Yamaguchi S, Konishi K, Hashimoto K. Mita J, et al. Among authors: hashimoto k. Cancer Diagn Progn. 2024 May 3;4(3):301-308. doi: 10.21873/cdp.10324. eCollection 2024 May-Jun. Cancer Diagn Progn. 2024. PMID: 38707741 Free PMC article.
7,685 results